Creative Medical Technology Holdings, Inc. CELZ
Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) is a pain/anesthesia drug developer. Its lead program, Olastrocel (CELZ 201), is in Phase 2 for Chronic lower back pain due to degenerative disc disease. Its next catalyst on record is Olastrocel (CELZ 201): Complete enrollment of expanded ADAPT cohort (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Olastrocel (CELZ 201) — Complete enrollment of expanded ADAPT cohort (date not stated). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Olastrocel (CELZ 201) | Chronic lower back pain due to degenerative disc disease | cell therapy | Phase 2 |
| Ultrasome | Osteoarthritis of the knee | cell therapy | Phase 1 |
| CELZ-201 | Managing abnormal glucose tolerance and preventing Type I Diabetes | cell therapy | Pre-clinical |
| Project PHOENIX / CELZ Biodefense Platform | Toxic environmental exposures (burn pits) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 pain/anesthesia companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.